drugset / Trial / NCT03393611
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Phase 1
Completed
14 enrolled
Weill Medical College of Cornell University
Jazz Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This pilot study is designed to evaluate outcomes with the combination of CPX-351 salvage therapy and haplo-cord graft stem cell transplantation for subjects with relapsed or refractory AML or myelodysplastic syndrome.
Timeline
- Start
- 2012-11-30
- Primary completion
- 2021-08-30
- Completion
- 2021-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | 120 unknown | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Melphalan | Small molecule | 140 mg/m2 | — |
| Background | Thymoglobulin | Protein / enzyme biologic | 1.5 mg/kg | — |